Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

被引：0
|
作者：
Schonhoft, Joseph [1 ]
Jendrisak, Adam [1 ]
Lee, Jerry [1 ]
Rodriguez, Angel [1 ]
Sutton, Ramsay [1 ]
Wang, Yipeng [1 ]
Dittamore, Ryan [1 ]
Landers, Mark [1 ]
机构：
[1] Epic Sci, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2228
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [12] BURDEN OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN TURKEY
    Erdal, E.
    Malhan, S.
    Oksuz, E.
    Benekli, M.
    Cag, C.
    Dane, F.
    Kabasakal, L.
    Kucuk, O.
    Sozen, T. S.
    Sar, C.
    Kahveci, B.
    VALUE IN HEALTH, 2016, 19 (07) : A725 - A726
  • [13] Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
    Paredero Perez, I.
    Arnal, M.
    Lorente, D.
    Girones Sarrio, R.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Llacer Perez, C.
    Castro Marcos, E.
    Olmos, D.
    Sanchez Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S526 - S526
  • [14] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [15] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [16] Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Fea, E.
    Vanella, P.
    Miraglio, E.
    Cauchi, C.
    Colantonio, I.
    Denaro, N.
    Di Costanzo, G.
    Garrone, O.
    Granetto, C.
    Occelli, M.
    Ricci, V.
    Vandone, A. M.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [17] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [18] Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Maurice-Dror, Corinne
    Fonseca, Nicolette
    Herberts, Cameron
    Fan, William
    Wyatt, Alexander W.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.
    Scher, Howard I.
    Heller, Glenn
    Yu, Margaret K.
    Kheoh, Thian
    Peng, Weimin
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [20] Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC).
    Keegan, Niamh M.
    Arfe, Andrea
    Barnett, Ethan
    Cohn, Erica Dayan
    Zhao, Jimmy
    Carbone, Emily
    Zanone, Michelle
    Anderson, Amanda
    Wenstrup, Rick
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345